Literature DB >> 18697392

Acyclovir susceptibility of herpes simplex virus isolates at King Chulalongkorn Memorial Hospital, Bangkok.

Ajchariyarat Sangdara1, Parvapan Bhattarakosol.   

Abstract

OBJECTIVE: To determine the ACV susceptibility in Thai HSV clinical isolates. MATERIAL AND
METHOD: One hundred thirty HSV isolates from the Virology Laboratory Unit, King Chulalongkorn Memorial Hospital, Bangkok Thailand had typing done by immunofluoresent assay using monoclonal antibody specific to either HSV-1 or HSV-2. Their sensitivity to ACV (IC50) was determined by plaque reduction assay.
RESULTS: The IC50 of 77 HSV-1 isolates ranged from 0.07-0.97 microg/ml and that of 53 HSV-2 isolates was 0.13-1.66 microg/ml. The standard HSV-1 (KOS) and HSV-2 (Baylor 186) were included in each run. The mean + standard deviation (SD) of ACV IC50 among HSV-1 and HSV-2 isolates were 0.38 +/- 0.23 and 0.50 +/- 0.32 microg/ml while that of standard HSV-1 and HSV-2 were 0.45 +/- 0.13 and 0.57 +/- 0.04 microg/ml. Statistically significant difference between IC50 of HSV-1 and HSV-2 isolates was indicated (p = 0.02).
CONCLUSION: No ACV(r) HSV has been detected and ACV susceptibility of HSV-2 has more resistance than that of HSV-1.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18697392

Source DB:  PubMed          Journal:  J Med Assoc Thai        ISSN: 0125-2208


  4 in total

1.  Valacyclovir for herpes simplex encephalitis.

Authors:  Thomas Pouplin; Julie Nguyen Pouplin; Pham Van Toi; Niklas Lindegardh; H Rogier van Doorn; Tran Tinh Hien; Jeremy Farrar; M Estée Török; Tran Thi Hong Chau
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

2.  Ionic derivatives of betulinic acid exhibit antiviral activity against herpes simplex virus type-2 (HSV-2), but not HIV-1 reverse transcriptase.

Authors:  Robert J Visalli; Hannah Ziobrowski; Kameswara R Badri; Johnny J He; Xiugen Zhang; Sri Ranjini Arumugam; Hua Zhao
Journal:  Bioorg Med Chem Lett       Date:  2015-06-06       Impact factor: 2.823

3.  VALZ-Pilot: High-dose valacyclovir treatment in patients with early-stage Alzheimer's disease.

Authors:  Bodil Weidung; Eva-Stina Hemmingsson; Jan Olsson; Torbjörn Sundström; Kaj Blennow; Henrik Zetterberg; Martin Ingelsson; Fredrik Elgh; Hugo Lövheim
Journal:  Alzheimers Dement (N Y)       Date:  2022-03-14

4.  Identifying HSV-1 Inhibitors from Natural Compounds via Virtual Screening Targeting Surface Glycoprotein D.

Authors:  Jiadai Wu; Helen Power; Monica Miranda-Saksena; Peter Valtchev; Aaron Schindeler; Anthony L Cunningham; Fariba Dehghani
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.